Prot#GS-US-324-0101: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/29/123/1/18

Funding

  • PRA Health Sciences (GS-US-324-0101)
  • Gilead Sciences, Inc. (GS-US-324-0101)